Table 1.
Demographics and Treatment Characteristics (N = 53)
| Characteristic | Value |
|---|---|
| Female sex, n (%) | 19 (35.85) |
| Age at time of transplant, yr, median (IQR) | 58.10 (52.87-66.32) |
| Disease (indication for HSCT), n (%) | |
| Acute lymphoblastic leukemia | 5 (9.43) |
| Acute myeloid leukemia | 18 (33.96) |
| Chronic myeloid leukemia | 2 (3.77) |
| Hemoglobinopathy | 1 (1.89) |
| Hodgkin lymphoma | 4 (7.55) |
| Myelodysplastic syndrome | 11 (20.75) |
| Myeloproliferative neoplasm | 4 (7.55) |
| Non-Hodgkin lymphoma | 3 (5.66) |
| Other acute leukemia | 2 (3.77) |
| Other leukemia | 3 (5.66) |
| Transplant type, n (%) | |
| Matched related | 29 (54.72) |
| Mismatched related | 1 (1.89) |
| Haploidentical related | 23 (43.40) |
| Conditioning regimen type | |
| Reduced intensity | 35 (66.04) |
| Myeloablative | 18 (33.96) |
| GVHD prophylaxis regimen, n (%) | |
| Cyclophosphamide, mycophenolate mofetil, tacrolimus | 26 (49.06) |
| Methotrexate, sirolimus, tacrolimus | 1 (1.89) |
| Methotrexate, tacrolimus | 24 (45.28) |
| None* | 2 (3.77) |
| History of acute GVHD, n (%) | 23 (43.40) |
| History of chronic GVHD in first 6 mo, n (%) | 3 (5.66) |
⁎
Participants were in a clinical trial to study immunosuppression-free regulatory T cell graft-engineered haploidentical HSCT.